The fluoropyrimidine 5-fluorouracil (5-FU) and its prodrug capecitabine are cytotoxic agents that have been widely used in the treatment of solid tumors. In the United States alone, an estimated 275,000 patients with cancer receive 5-FU each year. Despite its lifesaving/life-prolonging potential, 5-FU causes severe early-onset toxicity in up to one-fourth of patients, and more than 1300 die each year as a result of this toxicity.
Although administration and toxicity may differ between the 2 agents, they share the same risks for early-onset toxicity and overdosage, the signs of which are easily dismissed by patients and providers as expected chemotherapy-related adverse events.
The Importance of Patient Education in the Management of Treatment-Related Toxicities: A Nurse’s Perspective
Many healthcare providers who work in gastrointestinal oncology may feel blasé about the administration of 5-fluorouracil (5-FU), which is certainly the most commonly used chemotherapy in this setting.
There is nothing that pulls at my heart strings more than the sight of a young child dealing with a diagnosis of cancer. This issue of Conquering the Cancer Care Continuum™ focuses on pediatric cancer care, a challenging area of oncology management, but one in which amazing progress is being made.
The birth of the pediatric hematology/oncology specialty can be traced back to the early part of the 20th century, when pediatricians began describing hematologic abnormalities in infants and children.
As a practitioner in adult oncology, it is only on rare occasions that I see pediatric patients managed in our clinic. Generally speaking, such patients seen in this setting are mid-adolescents with diagnoses of Hodgkin lymphoma who are being treated with a standard adult regimen.
Cure rates for children with cancer now exceed 80% in high-income countries (HIC), but several challenges remain.
We have been hearing about the Affordable Care Act (ACA) for quite a while. However, many are still confused as to what this law is trying to accomplish and how it will benefit various populations of patients across the United States.
In 2010, Congress passed (and the President signed into law) comprehensive healthcare legislation called the Patient Protection and Affordable Care Act (PPACA), or as it is more commonly known, the Affordable Care Act (ACA).
In the spring of 2008, while I was finishing my oncology pharmacy residency training, I had the opportunity to spend a month in a prominent urban hospital very well known for its indigent patient population.
Page 1 of 4
Results 1 - 10 of 33
Results 1 - 10 of 33